Geocillin (carbenicillin indanyl sodium) is indicated in the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of the following organisms:

Escherichia coli
Proteus mirabilis
Morganella morganii (formerly Proteus morganii)
Providencia rettgeri (formerly Proteus rettgeri)
Proteus vulgaris
Pseudomonas
Enterobacter
Enterococci

Geocillin is also indicated in the treatment of prostatitis due to susceptible strains of the following organisms:

Escherichia coli
   Enterococcus (S. faecalis)
Proteus mirabilis
Enterobacter sp.

WHEN HIGH AND RAPID BLOOD AND URINE LEVELS OF ANTIBIOTIC ARE INDICATED, THERAPY WITH GEOPEN (CARBENICILLIN DISODIUM) SHOULD BE INITIATED BY PARENTERAL ADMINISTRATION FOLLOWED, AT THE PHYSICIAN'S DISCRETION, BY ORAL THERAPY.

NOTE: Susceptibility testing should be performed prior to and during the course of therapy to detect the possible emergence of resistant organisms which may develop.

To reduce the development of drug-resistant bacteria and maintain effectiveness of Geocillin and other antibacterial drugs, Geocillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Geocillin is available as a coated tablet to be administered orally.

Usual Adult Dose

Geocillin is available as film-coated tablets in bottles of 100's (NDC 0049-1430-66). Each tablet contains carbenicillin indanyl sodium equivalent to 382 mg of carbenicillin.

Distributed by: Roerig, Division of Pfizer Inc., NY, NY 10017, May 2007. FDA revision date: 2/27/2008

Bookmark this page: